Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
69.50    1.00 (1.46%)
Bid:
68.00
Ask:
71.00
Spread: 3.00 (4.412%)
Market Cap: £316.30m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
19th Jul 20163:13 pmRNSHolding(s) in Company
19th Jul 20167:15 amRNSHardman report: New Affimer opportunities
14th Jul 20167:00 amRNSCollaboration with Glythera
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20167:00 amRNSAffimer Binders for Zika Virus Diagnostics
16th Jun 201611:08 amRNSIssue of Equity
13th Jun 20167:00 amRNSCollaboration with Mologic
29th Apr 20163:04 pmRNSDirector's Dealing
25th Apr 20167:00 amRNSHalf-year Report
19th Apr 20167:00 amRNSAffimer Therapeutic Platform Development Milestone
7th Apr 20167:00 amRNSDirector's Dealing
5th Apr 20167:00 amRNSInvestor Evening
15th Mar 20167:00 amRNSIssue of Equity
7th Mar 20167:00 amRNSAvacta Establishes Scientific Advisory Board
25th Feb 20164:34 pmRNSHolding(s) in Company
24th Feb 20167:00 amRNSGrant Funding Awarded
23rd Feb 201610:54 amRNSHardman & Co Issues Research Report
23rd Feb 20167:00 amRNSDirector's Dealing
17th Feb 20167:00 amRNSDirectors' Dealings and Issue of Equity
26th Jan 20168:05 amRNSShare Consolidation
25th Jan 20163:35 pmRNSResult of Annual General Meeting
25th Jan 20167:01 amRNSPre-close trading update
25th Jan 20167:00 amRNSPhilippe Cotrel Appointed Chief Commercial Officer
21st Jan 20167:00 amRNSProposed Shareholder Consolidation
7th Jan 20167:00 amRNSPosting of Annual Report & Accounts and AGM Notice
5th Jan 20167:00 amRNSIssue of Equity
10th Dec 20157:00 amRNSAppointment of Tony Gardiner as CFO
1st Dec 20154:44 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSIssue of Equity
23rd Nov 20157:00 amRNSIssue of Equity
6th Nov 201510:56 amRNSHolding(s) in Company
30th Oct 20157:00 amRNSIssue of Equity
26th Oct 20157:00 amRNSFinal Results
19th Oct 20157:00 amRNSAffimers improve disease resistance in plants
9th Oct 20157:00 amRNSRobust performance of Affimers on Luminex platform
8th Oct 20157:00 amRNSNotice of Results
17th Sep 20157:00 amRNSAppoints Dr Mike Owen as Non-executive Director
10th Sep 20157:00 amRNSTotal Voting Rights
3rd Sep 20157:00 amRNSIssue of Equity
5th Aug 201510:00 amRNSHolding(s) in Company
5th Aug 20157:00 amRNSHolding(s) in Company
4th Aug 201510:18 amRNSIssue of Equity
31st Jul 201510:42 amRNSResult of General Meeting
23rd Jul 20157:00 amRNSIssue of Equity
15th Jul 20157:00 amRNSConditional Placing to Raise up to £22.0 Million
7th Jul 20158:00 amRNSBoard Change
7th Jul 20157:00 amRNSPre-Close Trading Update
20th May 201511:48 amRNSHolding(s) in Company
19th May 201512:42 pmRNSHolding(s) in Company
11th May 20157:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.